286836-05-3 Usage
Uses
Used in Pharmaceutical Synthesis:
7-Bromo-6-fluorobenzofuran is used as a key intermediate in the synthesis of pharmaceuticals for its ability to functionalize and modify other molecules, contributing to the development of new drugs with improved therapeutic properties.
Used in Agrochemical Synthesis:
In the agrochemical industry, 7-Bromo-6-fluorobenzofuran serves as a building block for the creation of novel agrochemicals, enhancing crop protection and management strategies.
Used in Medicinal Chemistry Research:
7-Bromo-6-fluorobenzofuran is utilized as a research compound in medicinal chemistry, exploring its potential applications and interactions with biological targets to advance drug discovery.
Used in Material Science:
Its unique structural features make 7-Bromo-6-fluorobenzofuran a candidate for material science applications, where it can be employed to develop new materials with specific properties for various industries.
Used in Chemical Research:
7-Bromo-6-fluorobenzofuran is also used in broader chemical research to study its reactivity, stability, and potential use in the synthesis of complex organic molecules.
Check Digit Verification of cas no
The CAS Registry Mumber 286836-05-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,8,6,8,3 and 6 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 286836-05:
(8*2)+(7*8)+(6*6)+(5*8)+(4*3)+(3*6)+(2*0)+(1*5)=183
183 % 10 = 3
So 286836-05-3 is a valid CAS Registry Number.
286836-05-3Relevant articles and documents
Pyridopyrimidinone compound and application thereof
-
Paragraph 0317-0318, (2021/01/24)
The invention provides a pyridopyrimidinone compound with a structure as shown in a general formula (II) and application thereof. Researches prove that the compound provided by the invention can effectively inhibit KRAS G12C mutation. KRAS mutation accounts for a large proportion in tumors, no approved drug is obtained for treatment at present, and the compound provided by the invention has the potential to become a therapeutic drug for malignant tumors (especially non-small cell lung cancer (NSCLC) and colorectal cancer) carrying KRAS G12C mutation, and has a great application value.
Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists
-
Page/Page column 23, (2010/11/08)
The present invention provides serotonergic aminoalkylbenzofurans of Formula (I): where R, R1, R2, R3, R4, R4′, R5, R5′, and R12 are as described in the specification.
SEROTONERGIC BENZOFURANS
-
Page/Page column 17, (2010/02/04)
The present invention provides serotonergic benzofurans of Formula (I): where A, R, R, R, R, and R are as described in the specification.
BENZOFURYLPIPERAZINES AND BENZOFURYLHOMOPIPERAZINES: SEROTONIN AGONISTS
-
, (2013/12/12)
The present invention provides serotonergic benzofurylpiperazines of Formula I: where: A is a piperazine of formula: and R, R1, R2, R3, R4, R5, R5', R6, R6', R7, R7', R8, and R8' are as described in the specification.